| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| 2',5'-Oligoadenylate Synthetase | 2 | 2021 | 205 | 0.41 | Why? |
| Glucocorticoids | 2 | 2020 | 4431 | 0.33 | Why? |
| Critical Illness | 2 | 2021 | 17281 | 0.33 | Why? |
| Biomedical Research | 2 | 2021 | 5270 | 0.27 | Why? |
| United Kingdom | 16 | 2021 | 18046 | 0.25 | Why? |
| Sepsis | 1 | 2019 | 3517 | 0.23 | Why? |
| Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2020 | 73 | 0.22 | Why? |
| Chromosomes, Human, Pair 19 | 1 | 2020 | 77 | 0.22 | Why? |
| Chromosomes, Human, Pair 12 | 1 | 2020 | 84 | 0.22 | Why? |
| Chromosomes, Human, Pair 21 | 1 | 2020 | 90 | 0.22 | Why? |
| TYK2 Kinase | 1 | 2020 | 116 | 0.22 | Why? |
| Receptors, CCR2 | 1 | 2020 | 103 | 0.22 | Why? |
| Evidence-Based Emergency Medicine | 1 | 2020 | 48 | 0.21 | Why? |
| Hemagglutination Tests | 1 | 2021 | 124 | 0.21 | Why? |
| Exome | 1 | 2021 | 207 | 0.20 | Why? |
| Multigene Family | 1 | 2020 | 377 | 0.20 | Why? |
| Genome-Wide Association Study | 3 | 2021 | 1648 | 0.19 | Why? |
| Whole Exome Sequencing | 1 | 2021 | 437 | 0.19 | Why? |
| Genetic Fitness | 1 | 2021 | 339 | 0.18 | Why? |
| Receptor, Interferon alpha-beta | 1 | 2020 | 610 | 0.18 | Why? |
| Clinical Protocols | 4 | 2021 | 2734 | 0.17 | Why? |
| Acclimatization | 1 | 2018 | 69 | 0.17 | Why? |
| Altitude Sickness | 1 | 2018 | 95 | 0.16 | Why? |
| Platelet Function Tests | 1 | 2018 | 231 | 0.16 | Why? |
| Hospitalization | 11 | 2021 | 54280 | 0.16 | Why? |
| Clinical Deterioration | 1 | 2021 | 473 | 0.16 | Why? |
| Genetic Predisposition to Disease | 2 | 2021 | 4027 | 0.15 | Why? |
| Intensive Care Units | 2 | 2021 | 29594 | 0.15 | Why? |
| Capacity Building | 1 | 2021 | 683 | 0.15 | Why? |
| Hospital Mortality | 8 | 2021 | 22087 | 0.14 | Why? |
| Altitude | 1 | 2018 | 311 | 0.13 | Why? |
| Idiopathic Pulmonary Fibrosis | 1 | 2021 | 595 | 0.13 | Why? |
| Chromosomes, Bacterial | 1 | 2013 | 18 | 0.13 | Why? |
| Methicillin Resistance | 1 | 2013 | 77 | 0.13 | Why? |
| Cooperative Behavior | 1 | 2021 | 1216 | 0.13 | Why? |
| Steroids | 1 | 2019 | 904 | 0.12 | Why? |
| Pneumothorax | 1 | 2021 | 758 | 0.12 | Why? |
| Thrombelastography | 1 | 2018 | 627 | 0.12 | Why? |
| Critical Care | 5 | 2021 | 14081 | 0.11 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2021 | 10649 | 0.11 | Why? |
| World Health Organization | 5 | 2021 | 4213 | 0.11 | Why? |
| Continuous Positive Airway Pressure | 1 | 2020 | 1187 | 0.11 | Why? |
| Inflammation | 4 | 2021 | 13255 | 0.11 | Why? |
| Respiration, Artificial | 6 | 2021 | 22116 | 0.11 | Why? |
| Immune Evasion | 1 | 2021 | 2081 | 0.10 | Why? |
| Minority Groups | 1 | 2021 | 1631 | 0.10 | Why? |
| Multiple Organ Failure | 1 | 2021 | 1724 | 0.10 | Why? |
| Lung Diseases, Interstitial | 1 | 2020 | 1476 | 0.10 | Why? |
| Genome, Bacterial | 1 | 2013 | 446 | 0.10 | Why? |
| Oxygen | 2 | 2020 | 3715 | 0.10 | Why? |
| Betacoronavirus | 10 | 2020 | 204454 | 0.09 | Why? |
| Dexamethasone | 1 | 2020 | 2055 | 0.09 | Why? |
| Humans | 40 | 2021 | 930598 | 0.09 | Why? |
| Immunoglobulins | 1 | 2014 | 811 | 0.09 | Why? |
| Coronavirus Infections | 12 | 2020 | 253789 | 0.09 | Why? |
| Internationality | 1 | 2021 | 3297 | 0.09 | Why? |
| Immunologic Memory | 1 | 2020 | 3362 | 0.09 | Why? |
| Pneumonia, Viral | 11 | 2020 | 243684 | 0.09 | Why? |
| Blood Coagulation Disorders | 1 | 2021 | 2040 | 0.09 | Why? |
| International Cooperation | 1 | 2021 | 3436 | 0.09 | Why? |
| Clinical Decision-Making | 1 | 2021 | 3755 | 0.08 | Why? |
| Evidence-Based Medicine | 1 | 2020 | 3228 | 0.08 | Why? |
| Oxygen Inhalation Therapy | 1 | 2020 | 3629 | 0.08 | Why? |
| Staphylococcus aureus | 1 | 2013 | 844 | 0.08 | Why? |
| Communicable Diseases, Emerging | 1 | 2020 | 2523 | 0.08 | Why? |
| Transcriptome | 1 | 2019 | 3466 | 0.07 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2020 | 4545 | 0.07 | Why? |
| Artificial Intelligence | 1 | 2020 | 3543 | 0.07 | Why? |
| Hospitals | 2 | 2021 | 11793 | 0.07 | Why? |
| Comorbidity | 4 | 2021 | 34796 | 0.07 | Why? |
| Plasma | 1 | 2014 | 1809 | 0.07 | Why? |
| Observational Studies as Topic | 2 | 2021 | 1887 | 0.07 | Why? |
| Male | 18 | 2021 | 367725 | 0.06 | Why? |
| Obesity | 2 | 2021 | 7388 | 0.06 | Why? |
| Lung | 3 | 2021 | 31049 | 0.06 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 3832 | 0.06 | Why? |
| Female | 18 | 2021 | 380317 | 0.06 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2020 | 5837 | 0.06 | Why? |
| Antigens, Viral | 1 | 2020 | 6298 | 0.06 | Why? |
| Cohort Studies | 6 | 2021 | 36005 | 0.06 | Why? |
| Asthma | 1 | 2021 | 4383 | 0.06 | Why? |
| Spike Glycoprotein, Coronavirus | 3 | 2021 | 37182 | 0.06 | Why? |
| Drug Repositioning | 1 | 2020 | 5683 | 0.06 | Why? |
| Mucin-5B | 1 | 2021 | 24 | 0.06 | Why? |
| Risk | 3 | 2021 | 5288 | 0.06 | Why? |
| Severity of Illness Index | 5 | 2021 | 48226 | 0.05 | Why? |
| Interleukin-1alpha | 1 | 2020 | 42 | 0.05 | Why? |
| Immunogenetics | 1 | 2020 | 124 | 0.05 | Why? |
| Agglutination Tests | 1 | 2021 | 124 | 0.05 | Why? |
| Prospective Studies | 6 | 2021 | 43301 | 0.05 | Why? |
| Aged | 13 | 2021 | 215776 | 0.05 | Why? |
| Cyclophilin A | 1 | 2020 | 90 | 0.05 | Why? |
| Aged, 80 and over | 8 | 2021 | 88759 | 0.05 | Why? |
| Virulence | 2 | 2021 | 2172 | 0.05 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2020 | 6653 | 0.05 | Why? |
| CD3 Complex | 1 | 2020 | 237 | 0.05 | Why? |
| Microtubule-Associated Proteins | 1 | 2020 | 187 | 0.05 | Why? |
| Injections, Intravenous | 1 | 2020 | 381 | 0.05 | Why? |
| CD4 Antigens | 1 | 2020 | 306 | 0.05 | Why? |
| Cross Infection | 1 | 2021 | 8675 | 0.05 | Why? |
| Respiratory Insufficiency | 1 | 2020 | 7301 | 0.05 | Why? |
| Odds Ratio | 2 | 2021 | 5861 | 0.05 | Why? |
| Sample Size | 1 | 2021 | 518 | 0.05 | Why? |
| Sequence Analysis | 1 | 2020 | 496 | 0.05 | Why? |
| Cytokines | 1 | 2021 | 15010 | 0.05 | Why? |
| Histones | 1 | 2021 | 371 | 0.05 | Why? |
| SARS Virus | 2 | 2020 | 13021 | 0.05 | Why? |
| DNA, Complementary | 1 | 2020 | 568 | 0.05 | Why? |
| Fluorescent Antibody Technique | 1 | 2021 | 835 | 0.04 | Why? |
| Gene Editing | 1 | 2021 | 330 | 0.04 | Why? |
| Polymorphism, Single Nucleotide | 2 | 2021 | 3607 | 0.04 | Why? |
| Bolivia | 1 | 2018 | 187 | 0.04 | Why? |
| Global Health | 1 | 2021 | 13911 | 0.04 | Why? |
| Middle Aged | 11 | 2021 | 270681 | 0.04 | Why? |
| Cyclosporine | 1 | 2020 | 449 | 0.04 | Why? |
| Tomography, X-Ray Computed | 2 | 2020 | 25144 | 0.04 | Why? |
| DNA, Viral | 2 | 2020 | 2521 | 0.04 | Why? |
| Pandemics | 12 | 2021 | 389249 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Chemokine CXCL10 | 1 | 2020 | 565 | 0.04 | Why? |
| Blood Coagulation | 2 | 2021 | 2768 | 0.04 | Why? |
| HIV Infections | 1 | 2021 | 11620 | 0.04 | Why? |
| Immunodominant Epitopes | 1 | 2020 | 813 | 0.04 | Why? |
| Thrombosis | 1 | 2018 | 7504 | 0.04 | Why? |
| Age Factors | 3 | 2021 | 21039 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 2 | 2020 | 12361 | 0.04 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 1 | 2017 | 8843 | 0.04 | Why? |
| Molecular Epidemiology | 1 | 2020 | 1638 | 0.03 | Why? |
| Databases, Genetic | 1 | 2020 | 1127 | 0.03 | Why? |
| HIV | 1 | 2021 | 1116 | 0.03 | Why? |
| Treatment Failure | 1 | 2020 | 2106 | 0.03 | Why? |
| Genomic Islands | 1 | 2013 | 26 | 0.03 | Why? |
| Program Development | 1 | 2020 | 1089 | 0.03 | Why? |
| Penicillin-Binding Proteins | 1 | 2013 | 31 | 0.03 | Why? |
| DNA Transposable Elements | 1 | 2013 | 91 | 0.03 | Why? |
| Respiratory Tract Diseases | 1 | 2021 | 1061 | 0.03 | Why? |
| Administration, Oral | 1 | 2020 | 2340 | 0.03 | Why? |
| Prognosis | 3 | 2021 | 32490 | 0.03 | Why? |
| Multiplex Polymerase Chain Reaction | 1 | 2020 | 1439 | 0.03 | Why? |
| Young Adult | 5 | 2021 | 93724 | 0.03 | Why? |
| CRISPR-Cas Systems | 1 | 2021 | 1397 | 0.03 | Why? |
| Genes, Bacterial | 1 | 2013 | 207 | 0.03 | Why? |
| Middle East | 1 | 2017 | 1418 | 0.03 | Why? |
| Diagnostic Imaging | 1 | 2020 | 1044 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2018 | 1444 | 0.03 | Why? |
| Biopsy | 1 | 2021 | 2811 | 0.03 | Why? |
| Repressor Proteins | 1 | 2013 | 232 | 0.03 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.03 | Why? |
| Hemostasis | 1 | 2018 | 811 | 0.03 | Why? |
| Neoplasms | 1 | 2020 | 17251 | 0.03 | Why? |
| Immune System | 1 | 2020 | 1479 | 0.03 | Why? |
| Seroconversion | 1 | 2021 | 2515 | 0.03 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.03 | Why? |
| Kaplan-Meier Estimate | 1 | 2020 | 4260 | 0.03 | Why? |
| Bacteriophages | 1 | 2013 | 268 | 0.03 | Why? |
| Proteomics | 1 | 2020 | 2481 | 0.02 | Why? |
| Autopsy | 1 | 2021 | 3495 | 0.02 | Why? |
| Adolescent | 4 | 2021 | 86841 | 0.02 | Why? |
| Epitopes, T-Lymphocyte | 1 | 2020 | 2262 | 0.02 | Why? |
| Infant, Newborn | 2 | 2020 | 23105 | 0.02 | Why? |
| DNA, Bacterial | 1 | 2013 | 835 | 0.02 | Why? |
| Species Specificity | 1 | 2013 | 1356 | 0.02 | Why? |
| Genomics | 1 | 2020 | 3118 | 0.02 | Why? |
| Phylogeny | 2 | 2021 | 13341 | 0.02 | Why? |
| Interferons | 1 | 2021 | 2885 | 0.02 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 3633 | 0.02 | Why? |
| Anti-Infective Agents | 1 | 2020 | 1766 | 0.02 | Why? |
| Adult | 6 | 2021 | 244371 | 0.02 | Why? |
| ROC Curve | 1 | 2020 | 6024 | 0.02 | Why? |
| Proteome | 1 | 2018 | 1812 | 0.02 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.02 | Why? |
| Point-of-Care Systems | 1 | 2021 | 2955 | 0.02 | Why? |
| Infant | 2 | 2020 | 30274 | 0.02 | Why? |
| Chronic Disease | 1 | 2021 | 5139 | 0.02 | Why? |
| Risk Assessment | 2 | 2021 | 25439 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2020 | 7268 | 0.02 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2021 | 2984 | 0.02 | Why? |
| New York City | 1 | 2020 | 7432 | 0.02 | Why? |
| Child, Preschool | 2 | 2020 | 36283 | 0.02 | Why? |
| Polymerase Chain Reaction | 1 | 2021 | 6740 | 0.02 | Why? |
| Open Reading Frames | 1 | 2013 | 1898 | 0.02 | Why? |
| Survival Rate | 1 | 2020 | 9206 | 0.02 | Why? |
| Logistic Models | 1 | 2021 | 9089 | 0.02 | Why? |
| Cell Line | 1 | 2021 | 12040 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 7868 | 0.02 | Why? |
| Computational Biology | 1 | 2020 | 4514 | 0.02 | Why? |
| Databases, Factual | 1 | 2020 | 6248 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2020 | 9537 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2013 | 2830 | 0.02 | Why? |
| Bacterial Proteins | 1 | 2013 | 1318 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2021 | 11304 | 0.02 | Why? |
| Patient Admission | 1 | 2021 | 5250 | 0.02 | Why? |
| Europe | 1 | 2020 | 12702 | 0.02 | Why? |
| Algorithms | 1 | 2020 | 7346 | 0.02 | Why? |
| Staphylococcal Infections | 1 | 2013 | 1099 | 0.02 | Why? |
| Radiography, Thoracic | 1 | 2020 | 5486 | 0.02 | Why? |
| Influenza, Human | 2 | 2021 | 10779 | 0.02 | Why? |
| Consensus | 1 | 2018 | 6345 | 0.02 | Why? |
| Sex Factors | 1 | 2020 | 11014 | 0.02 | Why? |
| Hypoxia | 1 | 2018 | 3626 | 0.02 | Why? |
| Nervous System Diseases | 1 | 2021 | 4092 | 0.01 | Why? |
| Length of Stay | 1 | 2020 | 11042 | 0.01 | Why? |
| Antibodies, Monoclonal | 1 | 2021 | 8041 | 0.01 | Why? |
| Disease Progression | 1 | 2020 | 13580 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 11367 | 0.01 | Why? |
| Child | 2 | 2020 | 70012 | 0.01 | Why? |
| Mutation | 1 | 2021 | 12376 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2021 | 22971 | 0.01 | Why? |
| Animals | 2 | 2021 | 78931 | 0.01 | Why? |
| Risk Factors | 2 | 2020 | 71621 | 0.01 | Why? |
| Viral Vaccines | 1 | 2020 | 7560 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.01 | Why? |
| Genome, Viral | 1 | 2020 | 13157 | 0.01 | Why? |
| Cardiovascular Diseases | 1 | 2021 | 11497 | 0.01 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.01 | Why? |
| Disease Transmission, Infectious | 1 | 2017 | 9044 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| Respiratory Tract Infections | 1 | 2014 | 6817 | 0.01 | Why? |
| RNA, Viral | 1 | 2020 | 32276 | 0.01 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2018 | 43792 | 0.01 | Why? |
| Retrospective Studies | 1 | 2020 | 105322 | 0.01 | Why? |